About us
Simris is a biotechnology company committed to transforming cancer treatment through its proprietary pipeline of next-generation ADC payloads. These payloads are born from world-class cyanobacterial science, proprietary conjugation methods, and collaborations with leading research institutions.
We are currently optimising novel Microcystin toxin variants for use in advanced ADCs, targeting both haematologic and solid tumours.
Our research team leverages close to 20 years of cyanobacteria expertise and our exclusive strain library to efficiently develop and scale novel payloads. This unique platform gives Simris a significant competitive edge in the emerging ADC landscape.
We operate a collaboration-first strategy, building value through partnerships with biopharma companies committed to delivering the next leap in targeted cancer therapies.
Simris Group is headquartered in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market (SIMRIS, ISIN: SE0008091664).
Name: Dr Alexis Roberts-McIntosh
Title: Chief Executive Officer since March 2024
Born: 1962
Alexis holds a PhD in Medicinal Chemistry, with an early career in GSK and has spent the last 27 years transitioning upwards through ever-more senior appointments at some of the world's global pharmaceutical companies including Pfizer, Johnson and Johnson and Abbott. Driving innovative healthcare products to commercialisation, managed complex teamsand large global P&Ls.
Non-Executive Director, Aureum DX Ltd.
Holdings: 0 B-shares, 0 warrants.